<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Nuvation Bio Inc — News on 6ix</title>
    <link>https://6ix.com/company/nuvation-bio-inc</link>
    <description>Latest news and press releases for Nuvation Bio Inc on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Mon, 27 Apr 2026 12:00:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/nuvation-bio-inc" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835a41878dffbe2df10a806.webp</url>
      <title>Nuvation Bio Inc</title>
      <link>https://6ix.com/company/nuvation-bio-inc</link>
    </image>
    <item>
      <title>Nuvation Bio Announces National Comprehensive Cancer Network® Adds Taletrectinib (IBTROZI®) as Recommended Option to Clinical Practice Guidelines in Oncology for Central Nervous System Cancers</title>
      <link>https://6ix.com/company/nuvation-bio-inc/news/nuvation-bio-announces-national-comprehensive-cancer-networkr-adds-taletrectinib-ibtrozir-as-recommended-option-to-clinical-practice-guidelines-in-oncology-for-central-nervous-system-cancers</link>
      <guid isPermaLink="true">https://6ix.com/company/nuvation-bio-inc/news/nuvation-bio-announces-national-comprehensive-cancer-networkr-adds-taletrectinib-ibtrozir-as-recommended-option-to-clinical-practice-guidelines-in-oncology-for-central-nervous-system-cancers</guid>
      <pubDate>Mon, 27 Apr 2026 12:00:00 GMT</pubDate>
      <description>Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that taletrectinib (IBTROZI®) has been added to the latest National Comprehensive Cancer Network® Clinical Practice Guidelines (NCCN Guidelines®) in Oncology for Central Nervous System (CNS) cancers, updated on April 24, 2026. Specifically, the NCCN Guidelines® for CNS Cancers now recommend taletrectinib (IBTROZI) as a systemic therapy option for ROS1</description>
    </item>
    <item>
      <title>Nuvation Bio Announces IBTROZI® (Taletrectinib) Showed Highly Durable Responses in Longer-Term Follow-up Data from Pivotal Studies Presented at AACR 2026</title>
      <link>https://6ix.com/company/nuvation-bio-inc/news/nuvation-bio-announces-ibtrozir-taletrectinib-showed-highly-durable-responses-in-longer-term-follow-up-data-from-pivotal-studies-presented-at-aacr-2026</link>
      <guid isPermaLink="true">https://6ix.com/company/nuvation-bio-inc/news/nuvation-bio-announces-ibtrozir-taletrectinib-showed-highly-durable-responses-in-longer-term-follow-up-data-from-pivotal-studies-presented-at-aacr-2026</guid>
      <pubDate>Tue, 21 Apr 2026 22:00:00 GMT</pubDate>
      <description>Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced results from a pooled analysis of long-term follow-up data from the pivotal TRUST-I and TRUST-II trials for IBTROZI® (taletrectinib) in patients with advanced ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC). The updated efficacy and safety results for both TKI-naïve and TKI-pretreated patients were presented at the American Association for Ca</description>
    </item>
    <item>
      <title>Nuvation Bio to Report First Quarter 2026 Financial Results and Provide Business Update on May 4, 2026</title>
      <link>https://6ix.com/company/nuvation-bio-inc/news/nuvation-bio-to-report-first-quarter-2026-financial-results-and-provide-business-update-on-may-4-2026</link>
      <guid isPermaLink="true">https://6ix.com/company/nuvation-bio-inc/news/nuvation-bio-to-report-first-quarter-2026-financial-results-and-provide-business-update-on-may-4-2026</guid>
      <pubDate>Mon, 20 Apr 2026 20:05:00 GMT</pubDate>
      <description>Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced it will host a conference call and webcast on Monday, May 4, 2026, at 4:30 p.m. ET to discuss its financial results and business updates for the first quarter of 2026.</description>
    </item>
    <item>
      <title>Nuvation Bio Announces Acquisition of Japan Rights to Safusidenib from Daiichi Sankyo</title>
      <link>https://6ix.com/company/nuvation-bio-inc/news/nuvation-bio-announces-acquisition-of-japan-rights-to-safusidenib-from-daiichi-sankyo</link>
      <guid isPermaLink="true">https://6ix.com/company/nuvation-bio-inc/news/nuvation-bio-announces-acquisition-of-japan-rights-to-safusidenib-from-daiichi-sankyo</guid>
      <pubDate>Wed, 01 Apr 2026 12:00:00 GMT</pubDate>
      <description>Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced the company has amended its existing exclusive license agreement for safusidenib with Daiichi Sankyo (TSE :4568) to include Japan rights, effectively securing exclusive global development and commercialization rights of the investigational medicine. The agreement, as amended, enables Nuvation Bio to expand its ongoing pivotal SIGMA study of safusideni</description>
    </item>
    <item>
      <title>Eisai and Nuvation Bio Announce Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated by the European Medicines Agency</title>
      <link>https://6ix.com/company/nuvation-bio-inc/news/eisai-and-nuvation-bio-announce-marketing-authorisation-application-for-taletrectinib-for-the-treatment-of-advanced-ros1-positive-non-small-cell-lung-cancer-validated-by-the-european-medicines-agency-1</link>
      <guid isPermaLink="true">https://6ix.com/company/nuvation-bio-inc/news/eisai-and-nuvation-bio-announce-marketing-authorisation-application-for-taletrectinib-for-the-treatment-of-advanced-ros1-positive-non-small-cell-lung-cancer-validated-by-the-european-medicines-agency-1</guid>
      <pubDate>Thu, 26 Mar 2026 20:05:00 GMT</pubDate>
      <description>Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, &quot;Eisai&quot;), a human-centered global leading research-based pharmaceutical company working in the neurology and oncology therapeutic areas, and Nuvation Bio Inc. (NYSE: NUVB, Corporate Headquarters: New York, NY, CEO: David Hung, M.D., &quot;Nuvation Bio&quot;), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that the European Medicines Agency (EMA) has validated the Marketing Authorisat</description>
    </item>
    <item>
      <title>Nuvation Bio to Present Pivotal IBTROZI® (Taletrectinib) Data in TKI-Naïve and TKI-Pretreated Patients with Advanced ROS1-Positive Non-Small Cell Lung Cancer at AACR 2026</title>
      <link>https://6ix.com/company/nuvation-bio-inc/news/nuvation-bio-to-present-pivotal-ibtrozir-taletrectinib-data-in-tki-naive-and-tki-pretreated-patients-with-advanced-ros1-positive-non-small-cell-lung-cancer-at-aacr-2026</link>
      <guid isPermaLink="true">https://6ix.com/company/nuvation-bio-inc/news/nuvation-bio-to-present-pivotal-ibtrozir-taletrectinib-data-in-tki-naive-and-tki-pretreated-patients-with-advanced-ros1-positive-non-small-cell-lung-cancer-at-aacr-2026</guid>
      <pubDate>Tue, 17 Mar 2026 20:35:00 GMT</pubDate>
      <description>Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that new data will be presented at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2026 taking place April 17–22, 2026, in San Diego, California. These data include updated results from the TRUST-I and TRUST-II clinical studies highlighting the efficacy and safety of IBTROZI® (taletrectinib) for the treatment of ROS1-positi</description>
    </item>
    <item>
      <title>Nuvation Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update</title>
      <link>https://6ix.com/company/nuvation-bio-inc/news/nuvation-bio-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-update</link>
      <guid isPermaLink="true">https://6ix.com/company/nuvation-bio-inc/news/nuvation-bio-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-update</guid>
      <pubDate>Mon, 02 Mar 2026 21:05:00 GMT</pubDate>
      <description>Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided a business update.</description>
    </item>
    <item>
      <title>Nuvation Bio to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 2, 2026</title>
      <link>https://6ix.com/company/nuvation-bio-inc/news/nuvation-bio-report-fourth-quarter-210500358</link>
      <guid isPermaLink="true">https://6ix.com/company/nuvation-bio-inc/news/nuvation-bio-report-fourth-quarter-210500358</guid>
      <pubDate>Tue, 17 Feb 2026 21:05:00 GMT</pubDate>
      <description>Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced it will host a conference call and webcast on Monday, March 2, 2026, at 4:30 p.m. ET to discuss its financial results and business updates for the fourth quarter and full year of 2025.</description>
    </item>
    <item>
      <title>Nuvation Bio Announces Pivotal Global Phase 3 SIGMA Trial (G203) for Safusidenib in IDH1-Mutant Glioma</title>
      <link>https://6ix.com/company/nuvation-bio-inc/news/nuvation-bio-announces-pivotal-global-130000809</link>
      <guid isPermaLink="true">https://6ix.com/company/nuvation-bio-inc/news/nuvation-bio-announces-pivotal-global-130000809</guid>
      <pubDate>Mon, 09 Feb 2026 13:00:00 GMT</pubDate>
      <description>NEW YORK, February 09, 2026--Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced finalization of a protocol amendment to the ongoing global SIGMA study (also known as G203; NCT05303519) of safusidenib that expands it to a Phase 3 trial. SIGMA is evaluating the efficacy and safety of safusidenib versus placebo for the maintenance treatment of patients with high-risk or high-grade IDH1-mutant astrocytoma</description>
    </item>
    <item>
      <title>Nuvation Bio Reports Preliminary Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook Ahead of 44th Annual J.P. Morgan Healthcare Conference</title>
      <link>https://6ix.com/company/nuvation-bio-inc/news/nuvation-bio-reports-preliminary-fourth-130000880</link>
      <guid isPermaLink="true">https://6ix.com/company/nuvation-bio-inc/news/nuvation-bio-reports-preliminary-fourth-130000880</guid>
      <pubDate>Mon, 12 Jan 2026 13:00:00 GMT</pubDate>
      <description>NEW YORK, January 12, 2026--Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced preliminary fourth quarter and full year 2025 net product revenue for IBTROZI® (taletrectinib) and provided a 2026 outlook ahead of its presentation at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA.</description>
    </item>
    <item>
      <title>Nuvation Bio and Eisai Enter into Exclusive Licensing Agreement for Taletrectinib in Europe and Additional Countries Outside U.S., China and Japan</title>
      <link>https://6ix.com/company/nuvation-bio-inc/news/nuvation-bio-eisai-enter-exclusive-123000494</link>
      <guid isPermaLink="true">https://6ix.com/company/nuvation-bio-inc/news/nuvation-bio-eisai-enter-exclusive-123000494</guid>
      <pubDate>Mon, 12 Jan 2026 12:30:00 GMT</pubDate>
      <description>NEW YORK &amp; TOKYO, January 12, 2026--Nuvation Bio Inc. (NYSE: NUVB, Corporate Headquarters: New York, NY, CEO: David Hung, M.D., &quot;Nuvation Bio&quot;), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, and Eisai Co., Ltd (Headquarters: Tokyo, CEO: Haruo Naito, &quot;Eisai&quot;), a human-centered global leading research-based pharmaceutical company working in the neurology and oncology therapeutic areas, today announced an exclusive license and collaboration agree</description>
    </item>
    <item>
      <title>Nuvation Bio to Present at the 44th Annual J.P. Morgan Healthcare Conference</title>
      <link>https://6ix.com/company/nuvation-bio-inc/news/nuvation-bio-present-44th-annual-210500924</link>
      <guid isPermaLink="true">https://6ix.com/company/nuvation-bio-inc/news/nuvation-bio-present-44th-annual-210500924</guid>
      <pubDate>Tue, 06 Jan 2026 21:05:00 GMT</pubDate>
      <description>NEW YORK, January 06, 2026--Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that David Hung, M.D., Founder, President, and Chief Executive Officer of Nuvation Bio, will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 3:45 p.m. PT (6:45 p.m. ET) in San Francisco, CA.</description>
    </item>
    <item>
      <title>Innovent Announces Inclusion of Seven Innovative Drugs including TYVYT New Indication and SYCUME in China&apos;s National Reimbursement Drug List</title>
      <link>https://6ix.com/company/nuvation-bio-inc/news/innovent-announces-inclusion-of-seven-innovative-drugs-including-tyvyt-new-indication-and-sycume-in-chinas-national-reimbursement-drug-list-1</link>
      <guid isPermaLink="true">https://6ix.com/company/nuvation-bio-inc/news/innovent-announces-inclusion-of-seven-innovative-drugs-including-tyvyt-new-indication-and-sycume-in-chinas-national-reimbursement-drug-list-1</guid>
      <pubDate>Sun, 07 Dec 2025 03:40:00 GMT</pubDate>
      <description>Innovent Biologics, Inc. (&quot;Innovent&quot;) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announces that seven of its innovative products have been included in the updated 2025 National Reimbursement Drug List (NRDL). This list features a new indication of TYVYT® (sintilimab injection), and first-time inclusions</description>
    </item>
    <item>
      <title>Nuvation Bio Announces Publication of Positive Phase 2 Study Results for Safusidenib for the Treatment of Grade 2 IDH1-Mutant Glioma in Neuro-Oncology</title>
      <link>https://6ix.com/company/nuvation-bio-inc/news/nuvation-bio-announces-publication-positive-130000267</link>
      <guid isPermaLink="true">https://6ix.com/company/nuvation-bio-inc/news/nuvation-bio-announces-publication-positive-130000267</guid>
      <pubDate>Wed, 03 Dec 2025 13:00:00 GMT</pubDate>
      <description>NEW YORK, December 03, 2025--Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced the publication of positive results from a Phase 2 study of safusidenib, a novel, oral, potent, brain-penetrant targeted inhibitor of mutant IDH1, in patients with chemotherapy- and radiotherapy-naïve grade 2 IDH1-mutant gliomas. The findings were first published online on November 8 in the journal of Neuro-Oncology.</description>
    </item>
    <item>
      <title>Nuvation Bio to Participate in Upcoming Investor Conferences</title>
      <link>https://6ix.com/company/nuvation-bio-inc/news/nuvation-bio-participate-upcoming-investor-210500996</link>
      <guid isPermaLink="true">https://6ix.com/company/nuvation-bio-inc/news/nuvation-bio-participate-upcoming-investor-210500996</guid>
      <pubDate>Wed, 26 Nov 2025 21:05:00 GMT</pubDate>
      <description>NEW YORK, November 26, 2025--Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that David Hung, M.D., Founder, President, and Chief Executive Officer of Nuvation Bio, and Philippe Sauvage, Chief Financial Officer of Nuvation Bio, will participate in fireside chats at two upcoming investor conferences:</description>
    </item>
    <item>
      <title>Nuvation Bio Reports Third Quarter 2025 Financial Results and Provides Business Update</title>
      <link>https://6ix.com/company/nuvation-bio-inc/news/nuvation-bio-reports-third-quarter-210500094</link>
      <guid isPermaLink="true">https://6ix.com/company/nuvation-bio-inc/news/nuvation-bio-reports-third-quarter-210500094</guid>
      <pubDate>Mon, 03 Nov 2025 21:05:00 GMT</pubDate>
      <description>NEW YORK, November 03, 2025--Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today reported financial results for the third quarter ended September 30, 2025, and provided a business update.</description>
    </item>
    <item>
      <title>Nuvation Bio Enrolls First Patient in Global, Randomized Study of Safusidenib for Maintenance Treatment of High-Grade IDH1-Mutant Glioma</title>
      <link>https://6ix.com/company/nuvation-bio-inc/news/nuvation-bio-enrolls-first-patient-113000775</link>
      <guid isPermaLink="true">https://6ix.com/company/nuvation-bio-inc/news/nuvation-bio-enrolls-first-patient-113000775</guid>
      <pubDate>Thu, 23 Oct 2025 11:30:00 GMT</pubDate>
      <description>NEW YORK, October 23, 2025--Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced enrollment of the first patient into part 2 of G203 (NCT05303519), a global, randomized study evaluating the efficacy and safety of safusidenib versus placebo for the maintenance treatment of patients with high-grade IDH1-mutant astrocytoma following standard-of-care radiation or chemoradiation and adjuvant temozolomide. Sa</description>
    </item>
    <item>
      <title>Nuvation Bio to Report Third Quarter 2025 Financial Results and Provide Business Update on November 3, 2025</title>
      <link>https://6ix.com/company/nuvation-bio-inc/news/nuvation-bio-report-third-quarter-200500395</link>
      <guid isPermaLink="true">https://6ix.com/company/nuvation-bio-inc/news/nuvation-bio-report-third-quarter-200500395</guid>
      <pubDate>Mon, 20 Oct 2025 20:05:00 GMT</pubDate>
      <description>NEW YORK, October 20, 2025--Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced it will host a conference call and webcast on Monday, November 3, 2025, at 4:30 p.m. ET to discuss its financial results and business updates for the third quarter of 2025.</description>
    </item>
    <item>
      <title>Nuvation Bio Enrolls First Patient in TRUST-IV Phase 3 Study of IBTROZI™ (taletrectinib) for the Adjuvant Treatment of ROS1-Positive Early-Stage Non-Small Cell Lung Cancer</title>
      <link>https://6ix.com/company/nuvation-bio-inc/news/nuvation-bio-enrolls-first-patient-113000346</link>
      <guid isPermaLink="true">https://6ix.com/company/nuvation-bio-inc/news/nuvation-bio-enrolls-first-patient-113000346</guid>
      <pubDate>Tue, 30 Sep 2025 11:30:00 GMT</pubDate>
      <description>NEW YORK, September 30, 2025--Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced it has enrolled the first patient in TRUST-IV (NCT07154706), a Phase 3 study evaluating the efficacy and safety of IBTROZI™ (taletrectinib), a next-generation ROS1 inhibitor, versus placebo for the adjuvant treatment of patients with resected ROS1-positive (ROS1+) early-stage non-small cell lung cancer (NSCLC).</description>
    </item>
    <item>
      <title>Nuvation Bio Receives Approval from Japan’s Ministry of Health, Labour and Welfare for IBTROZITM for Patients with Advanced ROS1-positive Non-Small Cell Lung Cancer</title>
      <link>https://6ix.com/company/nuvation-bio-inc/news/nuvation-bio-receives-approval-japan-113000291</link>
      <guid isPermaLink="true">https://6ix.com/company/nuvation-bio-inc/news/nuvation-bio-receives-approval-japan-113000291</guid>
      <pubDate>Fri, 19 Sep 2025 11:30:00 GMT</pubDate>
      <description>NEW YORK, September 19, 2025--Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved IBTROZITM (taletrectinib) for the treatment of adult patients with ROS1-positive (ROS1+) unresectable, advanced and/or recurrent non-small cell lung cancer (NSCLC). As part of an exclusive license agreement entered in 2023, Nippon Kayaku will commerci</description>
    </item>
  </channel>
</rss>